**Comparative Effectiveness and Safety of Biosimilar and Legacy Drugs**

## Inclusion/ Exclusion Criteria

Our study will include patients 18 years and older, with a clinical diagnosis of inflammatory rheumatic disease (either RA or AS), or IBD (CD or UC) who have given their informed consent. There are no disease activity criteria for entry. We will enrol all patients starting on a biosimilar or its bio-originator (as of 2020, for IBD the only biosimilar is infliximab, but adalimumab biosimilar is also on the horizon). Patients are not required to be biologic-naïve. At baseline and follow-ups, information on disease activity, co-morbidity, concomitant medication, and other variables are collected. The minimum information required is time on medication (or time to medication discontinuation) but more detailed analyses (including reasons for discontinuation and effectiveness for disease control, etc.) will be done for centres able to provide that data.